Docusign Financials
This page shows Docusign (DOCU) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
DocuSign’s profitability inflection has come from expense leverage and strong cash conversion, not a step-change in gross margin.
The recent earnings drop looks worse than the business trend because operating income rose to$299M from$200M . Net income fell to$309M from$1.07B , but that mostly unwinds a prior-year tax benefit rather than signaling weaker core operations.
The clearest operating shift is margin expansion without new product economics: gross margin stayed around
The model is also capital-light. In FY2026, operating cash flow was
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Docusign's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Docusign has an operating margin of 9.3%, meaning the company retains $9 of operating profit per $100 of revenue. This results in a moderate score of 47/100, indicating healthy but not exceptional operating efficiency. This is up from 6.7% the prior year.
Docusign's revenue grew 8.2% year-over-year to $3.2B, a solid pace of expansion. This earns a growth score of 60/100.
Docusign has a moderate D/E ratio of 1.19. This balance of debt and equity financing earns a leverage score of 43/100.
Docusign's current ratio of 0.66 is below the typical benchmark, resulting in a score of 8/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Docusign converts 32.9% of revenue into free cash flow ($1.1B). This strong cash generation earns a score of 95/100.
Docusign's ROE of 17.0% shows moderate profitability relative to equity, earning a score of 51/100. This is down from 53.0% the prior year.
Docusign scores 2.71, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($9.3B) relative to total liabilities ($2.2B). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Docusign passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Docusign generates $3.77 in operating cash flow ($1.2B OCF vs $309.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Docusign earns $117.3 in operating income for every $1 of interest expense ($298.6M vs $2.5M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Docusign generated $3.2B in revenue in fiscal year 2026. This represents an increase of 8.2% from the prior year.
Docusign's EBITDA was $414.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 34.7% from the prior year.
Docusign reported $309.1M in net income in fiscal year 2026. This represents a decrease of 71.1% from the prior year.
Docusign earned $1.48 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 70.9% from the prior year.
Cash & Balance Sheet
Docusign generated $1.1B in free cash flow in fiscal year 2026, representing cash available after capex. This represents an increase of 15.0% from the prior year.
Docusign held $548.0M in cash against $0 in long-term debt as of fiscal year 2026.
Docusign had 194M shares outstanding in fiscal year 2026. This represents a decrease of 4.0% from the prior year.
Margins & Returns
Docusign's gross margin was 79.4% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 0.3 percentage points from the prior year.
Docusign's operating margin was 9.3% in fiscal year 2026, reflecting core business profitability. This is up 2.6 percentage points from the prior year.
Docusign's net profit margin was 9.6% in fiscal year 2026, showing the share of revenue converted to profit. This is down 26.3 percentage points from the prior year.
Docusign's ROE was 17.0% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 36.0 percentage points from the prior year.
Capital Allocation
Docusign invested $665.0M in research and development in fiscal year 2026. This represents an increase of 13.0% from the prior year.
Docusign spent $869.1M on share buybacks in fiscal year 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 27.1% from the prior year.
Docusign invested $106.4M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 9.8% from the prior year.
DOCU Income Statement
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $830.2M-0.8% | $836.9M+2.3% | $818.4M+2.2% | $800.6M+4.8% | $763.7M-1.6% | $776.3M+2.8% | $754.8M+2.6% | $736.0M |
| Cost of Revenue | $171.3M+0.9% | $169.8M-0.4% | $170.5M+3.1% | $165.5M+5.2% | $157.3M-1.8% | $160.2M+2.3% | $156.5M+0.7% | $155.5M |
| Gross Profit | $659.0M-1.2% | $667.1M+3.0% | $647.8M+2.0% | $635.2M+4.7% | $606.4M-1.6% | $616.0M+3.0% | $598.3M+3.1% | $580.6M |
| R&D Expenses | $159.6M-5.2% | $168.3M+0.4% | $167.6M-1.2% | $169.6M+6.4% | $159.4M+2.6% | $155.5M+2.9% | $151.1M+2.4% | $147.6M |
| SG&A Expenses | $91.9M-12.9% | $105.5M+7.4% | $98.3M+3.6% | $94.9M+5.1% | $90.3M-8.7% | $98.8M+1.3% | $97.6M+12.0% | $87.1M |
| Operating Income | $111.3M+26.9% | $87.7M+2.8% | $85.4M+30.9% | $65.2M+8.3% | $60.3M-0.4% | $60.5M+2.4% | $59.0M+2.1% | $57.8M |
| Interest Expense | $551K-6.0% | $586K-10.4% | $654K-21.0% | $828K+73.2% | $478K+19.5% | $400K-13.4% | $462K-15.1% | $544K |
| Income Tax | $39.6M+251.8% | $11.2M-4.7% | $11.8M-12.5% | $13.5M+692.1% | $1.7M+110.9% | -$15.6M-270.5% | $9.2M+101.1% | -$816.3M |
| Net Income | $78.2M-13.4% | $90.3M+7.9% | $83.7M+33.0% | $63.0M-12.6% | $72.1M-13.7% | $83.5M+33.8% | $62.4M-93.0% | $888.2M |
| EPS (Diluted) | $0.40 | N/A | $0.40+33.3% | $0.30-11.8% | $0.34 | N/A | $0.30-93.0% | $4.26 |
DOCU Balance Sheet
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.0B-5.8% | $4.2B+6.2% | $4.0B+0.8% | $3.9B+0.1% | $3.9B-1.6% | $4.0B+6.4% | $3.8B+0.4% | $3.8B |
| Current Assets | $1.3B-15.8% | $1.5B+14.1% | $1.3B-0.9% | $1.3B-4.2% | $1.4B-7.5% | $1.5B+11.8% | $1.3B-0.9% | $1.3B |
| Cash & Equivalents | $548.0M-9.0% | $602.4M+3.3% | $583.3M-2.8% | $600.0M-8.7% | $657.4M+1.4% | $648.6M+6.2% | $610.9M-1.3% | $619.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $300.7M-41.8% | $516.4M+45.5% | $355.0M-0.6% | $356.9M+16.0% | $307.6M-28.4% | $429.6M+43.0% | $300.4M-3.0% | $309.9M |
| Goodwill | $459.1M+0.2% | $458.4M+0.3% | $457.2M+0.2% | $456.4M+0.2% | $455.3M+0.2% | $454.5M-0.3% | $455.7M0.0% | $455.5M |
| Total Liabilities | $2.2B-6.4% | $2.3B+15.6% | $2.0B+2.0% | $2.0B+1.5% | $1.9B-3.9% | $2.0B+12.9% | $1.8B-0.7% | $1.8B |
| Current Liabilities | $1.9B-7.4% | $2.0B+14.3% | $1.8B+0.4% | $1.8B+2.0% | $1.7B-4.9% | $1.8B+14.6% | $1.6B-0.5% | $1.6B |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.8B-5.1% | $1.9B-3.2% | $2.0B-0.3% | $2.0B-1.3% | $2.0B+0.6% | $2.0B+0.7% | $2.0B+1.4% | $2.0B |
| Retained Earnings | -$2.1B-12.9% | -$1.9B-11.3% | -$1.7B-8.6% | -$1.5B-9.9% | -$1.4B-8.7% | -$1.3B-6.4% | -$1.2B-10.1% | -$1.1B |
DOCU Cash Flow Statement
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $321.7M-14.7% | $377.2M+30.0% | $290.3M+18.0% | $246.1M-2.1% | $251.4M-18.3% | $307.9M+31.4% | $234.3M+6.4% | $220.2M |
| Capital Expenditures | $32.3M+19.4% | $27.0M-1.3% | $27.4M-3.7% | $28.4M+20.3% | $23.6M-16.6% | $28.3M+20.0% | $23.6M+6.0% | $22.3M |
| Free Cash Flow | $289.4M-17.4% | $350.2M+33.2% | $262.9M+20.8% | $217.6M-4.5% | $227.8M-18.5% | $279.6M+32.7% | $210.7M+6.5% | $197.9M |
| Investing Cash Flow | -$39.2M-16.6% | -$33.7M+10.8% | -$37.7M-24.0% | -$30.5M-22.2% | -$24.9M+22.8% | -$32.3M+26.1% | -$43.7M+75.2% | -$176.1M |
| Financing Cash Flow | -$334.4M-0.5% | -$332.6M-23.0% | -$270.5M+1.1% | -$273.3M-22.3% | -$223.5M+3.5% | -$231.5M-16.7% | -$198.3M+17.0% | -$239.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $317.5M+18.0% | $269.1M+25.1% | $215.1M+6.7% | $201.5M+9.9% | $183.4M+13.4% | $161.7M-6.3% | $172.7M-13.7% | $200.1M |
DOCU Financial Ratios
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.4%-0.3pp | 79.7%+0.6pp | 79.2%-0.2pp | 79.3%-0.1pp | 79.4%+0.1pp | 79.4%+0.1pp | 79.3%+0.4pp | 78.9% |
| Operating Margin | 13.4%+2.9pp | 10.5%+0.1pp | 10.4%+2.3pp | 8.2%+0.3pp | 7.9%+0.1pp | 7.8%-0.0pp | 7.8%-0.0pp | 7.8% |
| Net Margin | 9.4%-1.4pp | 10.8%+0.6pp | 10.2%+2.4pp | 7.9%-1.6pp | 9.4%-1.3pp | 10.8%+2.5pp | 8.3%-112.4pp | 120.7% |
| Return on Equity | 4.3%-0.4pp | 4.7%+0.5pp | 4.2%+1.1pp | 3.2%-0.4pp | 3.6%-0.6pp | 4.2%+1.0pp | 3.1%-42.1pp | 45.3% |
| Return on Assets | 2.0%-0.2pp | 2.1%+0.0pp | 2.1%+0.5pp | 1.6%-0.2pp | 1.8%-0.2pp | 2.1%+0.4pp | 1.7%-22.0pp | 23.7% |
| Current Ratio | 0.66-0.1 | 0.730.0 | 0.730.0 | 0.74-0.0 | 0.79-0.0 | 0.81-0.0 | 0.830.0 | 0.84 |
| Debt-to-Equity | 1.19-0.0 | 1.21+0.2 | 1.01+0.0 | 0.99+0.0 | 0.96-0.0 | 1.00+0.1 | 0.90-0.0 | 0.91 |
| FCF Margin | 34.9%-7.0pp | 41.9%+9.7pp | 32.1%+4.9pp | 27.2%-2.7pp | 29.8%-6.2pp | 36.0%+8.1pp | 27.9%+1.0pp | 26.9% |
Note: The current ratio is below 1.0 (0.66), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Docusign's annual revenue?
Docusign (DOCU) reported $3.2B in total revenue for fiscal year 2026. This represents a 8.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Docusign's revenue growing?
Docusign (DOCU) revenue grew by 8.2% year-over-year, from $3.0B to $3.2B in fiscal year 2026.
Is Docusign profitable?
Yes, Docusign (DOCU) reported a net income of $309.1M in fiscal year 2026, with a net profit margin of 9.6%.
What is Docusign's EBITDA?
Docusign (DOCU) had EBITDA of $414.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Docusign's gross margin?
Docusign (DOCU) had a gross margin of 79.4% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Docusign's operating margin?
Docusign (DOCU) had an operating margin of 9.3% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Docusign's net profit margin?
Docusign (DOCU) had a net profit margin of 9.6% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Docusign's return on equity (ROE)?
Docusign (DOCU) has a return on equity of 17.0% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Docusign's free cash flow?
Docusign (DOCU) generated $1.1B in free cash flow during fiscal year 2026. This represents a 15.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Docusign's operating cash flow?
Docusign (DOCU) generated $1.2B in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Docusign's total assets?
Docusign (DOCU) had $4.0B in total assets as of fiscal year 2026, including both current and long-term assets.
What are Docusign's capital expenditures?
Docusign (DOCU) invested $106.4M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Docusign spend on research and development?
Docusign (DOCU) invested $665.0M in research and development during fiscal year 2026.
What is Docusign's current ratio?
Docusign (DOCU) had a current ratio of 0.66 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
What is Docusign's debt-to-equity ratio?
Docusign (DOCU) had a debt-to-equity ratio of 1.19 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Docusign's return on assets (ROA)?
Docusign (DOCU) had a return on assets of 7.8% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Docusign's Altman Z-Score?
Docusign (DOCU) has an Altman Z-Score of 2.71, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Docusign's Piotroski F-Score?
Docusign (DOCU) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Docusign's earnings high quality?
Docusign (DOCU) has an earnings quality ratio of 3.77x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Docusign cover its interest payments?
Docusign (DOCU) has an interest coverage ratio of 117.3x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Docusign?
Docusign (DOCU) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.